Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value
$108.52+1.27 (+1.18%)
Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%
Abbott Laboratories r&d expenses
Research and development expenses are spending on new products and technology.
Abbott Laboratories's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.31B, up 12.1% year over year. For fiscal 2025 it was $2.94B, up 3.4% from the year before. Over ten years it grew 7.7% a year on average. The highest annual figure on record is $3.72B in fiscal 2010.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.94B | +3.4% |
| FY2024 | Dec 31, 2024 | $2.84B | +3.8% |
| FY2023 | Dec 31, 2023 | $2.74B | -5.1% |
| FY2022 | Dec 31, 2022 | $2.89B | +5.3% |
| FY2021 | Dec 31, 2021 | $2.74B | +13.3% |
| FY2020 | Dec 31, 2020 | $2.42B | -0.8% |
| FY2019 | Dec 31, 2019 | $2.44B | +6.1% |
| FY2018 | Dec 31, 2018 | $2.30B | +1.8% |
| FY2017 | Dec 31, 2017 | $2.26B | +56.2% |
| FY2016 | Dec 31, 2016 | $1.45B | +3.0% |
| FY2015 | Dec 31, 2015 | $1.41B | +4.5% |
| FY2014 | Dec 31, 2014 | $1.35B | -1.9% |
| FY2013 | Dec 31, 2013 | $1.37B | -6.2% |
| FY2012 | Dec 31, 2012 | $1.46B | -3.4% |
| FY2011 | Dec 31, 2011 | $1.51B | -59.4% |
| FY2010 | Dec 31, 2010 | $3.72B | +35.7% |
| FY2009 | Dec 31, 2009 | $2.74B | +2.0% |
| FY2008 | Dec 31, 2008 | $2.69B | +7.3% |
| FY2007 | Dec 31, 2007 | $2.51B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $920.00M | +20.1% |
| Q2 FY2026 | Jun 30, 2026 | $892.00M | +23.0% |
| Q1 FY2026 | Mar 31, 2026 | $767.00M | +7.1% |
| Q4 FY2025 | Dec 31, 2025 | $735.00M | -1.9% |
| Q3 FY2025 | Sep 30, 2025 | $766.00M | +7.4% |
| Q2 FY2025 | Jun 30, 2025 | $725.00M | +3.9% |
| Q1 FY2025 | Mar 31, 2025 | $716.00M | +4.7% |
| Q4 FY2024 | Dec 31, 2024 | $749.00M | +7.0% |
| Q3 FY2024 | Sep 30, 2024 | $713.00M | +6.1% |
| Q2 FY2024 | Jun 30, 2024 | $698.00M | -2.4% |
| Q1 FY2024 | Mar 31, 2024 | $684.00M | +4.6% |
| Q4 FY2023 | Dec 31, 2023 | $700.00M | -3.4% |
| Q3 FY2023 | Sep 30, 2023 | $672.00M | -14.1% |
| Q2 FY2023 | Jun 30, 2023 | $715.00M | +4.5% |
| Q1 FY2023 | Mar 31, 2023 | $654.00M | -6.2% |
| Q4 FY2022 | Dec 31, 2022 | $725.00M | -4.9% |
| Q3 FY2022 | Sep 30, 2022 | $782.00M | +16.4% |
| Q2 FY2022 | Jun 30, 2022 | $684.00M | +4.6% |
| Q1 FY2022 | Mar 31, 2022 | $697.00M | +6.6% |
| Q4 FY2021 | Dec 31, 2021 | $762.00M | +9.2% |
| Q3 FY2021 | Sep 30, 2021 | $672.00M | +15.9% |
| Q2 FY2021 | Jun 30, 2021 | $654.00M | +16.0% |
| Q1 FY2021 | Mar 31, 2021 | $654.00M | +13.1% |
| Q4 FY2020 | Dec 31, 2020 | $698.00M | +17.3% |
| Q3 FY2020 | Sep 30, 2020 | $580.00M | -2.7% |
| Q2 FY2020 | Jun 30, 2020 | $564.00M | -2.3% |
| Q1 FY2020 | Mar 31, 2020 | $578.00M | -14.0% |
| Q4 FY2019 | Dec 31, 2019 | $595.00M | +5.9% |
| Q3 FY2019 | Sep 30, 2019 | $596.00M | +3.8% |
| Q2 FY2019 | Jun 30, 2019 | $577.00M | +0.3% |
| Q1 FY2019 | Mar 31, 2019 | $672.00M | +14.1% |
| Q4 FY2018 | Dec 31, 2018 | $562.00M | -9.2% |
| Q3 FY2018 | Sep 30, 2018 | $574.00M | +1.1% |
| Q2 FY2018 | Jun 30, 2018 | $575.00M | +10.6% |
| Q1 FY2018 | Mar 31, 2018 | $589.00M | +6.5% |
| Q4 FY2017 | Dec 31, 2017 | $619.00M | +68.2% |
| Q3 FY2017 | Sep 30, 2017 | $568.00M | – |
| Q2 FY2017 | Jun 30, 2017 | $520.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $553.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $368.00M | – |
See a number that looks wrong?